81 related articles for article (PubMed ID: 23930676)
21. No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction.
Leusink M; de Keyser CE; Onland-Moret NC; Hofman A; Visser LE; Stricker BH; de Bakker PI; de Boer A; van Schaik RH; Maitland-van der Zee AH
Pharmacogenomics; 2014 Aug; 15(11):1471-7. PubMed ID: 25303298
[TBL] [Abstract][Full Text] [Related]
22. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
[TBL] [Abstract][Full Text] [Related]
23. Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol/l.
Undas A; Topór-Madry R; Tracz W
Pol Arch Med Wewn; 2009 Jun; 119(6):354-9. PubMed ID: 19694216
[TBL] [Abstract][Full Text] [Related]
24. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol.
Chaves FJ; Real JT; García-García AB; Civera M; Armengod ME; Ascaso JF; Carmena R
J Clin Endocrinol Metab; 2001 Oct; 86(10):4926-32. PubMed ID: 11600564
[TBL] [Abstract][Full Text] [Related]
25. Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients.
Averna M; Zaninelli A; Le Grazie C; Gensini GF
J Clin Lipidol; 2010; 4(4):272-8. PubMed ID: 21122660
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenetic study of statin therapy and cholesterol reduction.
Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
[TBL] [Abstract][Full Text] [Related]
27. The influence of apolipoprotein B and E gene polymorphisms on the response to simvastatin therapy in patients with hyperlipidemia.
Ye P; Shang Y; Ding X
Chin Med Sci J; 2003 Mar; 18(1):9-13. PubMed ID: 12901521
[TBL] [Abstract][Full Text] [Related]
28. Endothelial Effect of Statin Therapy at a High Dose Versus Low Dose Associated with Ezetimibe.
Garcia MM; Varela CG; Silva PF; Lima PR; Góes PM; Rodrigues MG; Silva Mde L; Ladeia AM; Guimarães AC; Correia LC
Arq Bras Cardiol; 2016 Apr; 106(4):279-88. PubMed ID: 27142792
[TBL] [Abstract][Full Text] [Related]
29. Identical LDL-cholesterol lowering but non-identical effects on NF-κB activity: High dose simvastatin vs combination therapy with ezetimibe.
Rudofsky G; Reismann P; Groener JB; Djuric Z; Fleming T; Metzner C; Grafe IA; Bierhaus A; Nawroth PP
Atherosclerosis; 2012 Jul; 223(1):190-6. PubMed ID: 22633472
[TBL] [Abstract][Full Text] [Related]
30. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.
Maki KC; Dicklin MR; Davidson MH; Doyle RT; Ballantyne CM;
Am J Cardiol; 2010 May; 105(10):1409-12. PubMed ID: 20451686
[TBL] [Abstract][Full Text] [Related]
31. 2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?
Bangalore S; Fayyad R; Kastelein JJ; Laskey R; Amarenco P; DeMicco DA; Waters DD
Am J Med; 2016 Apr; 129(4):384-91. PubMed ID: 26551986
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
[TBL] [Abstract][Full Text] [Related]
33. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
34. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
[TBL] [Abstract][Full Text] [Related]
35. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction.
Toth PP; Ballantyne CM; Davidson MH; Tomassini JE; Ramey DR; Neff D; Tershakovec AM; Hu XH; Tunceli K
J Clin Lipidol; 2012; 6(2):180-91. PubMed ID: 22385552
[TBL] [Abstract][Full Text] [Related]
36. Beneficial effect of simvastatin treatment on LDL oxidation and antioxidant protection is more pronounced in combined hyperlipidemia than in hypercholesterolemia.
Molcányiová A; Stancáková A; Javorský M; Tkác I
Pharmacol Res; 2006 Sep; 54(3):203-7. PubMed ID: 16737822
[TBL] [Abstract][Full Text] [Related]
37. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
38. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
Collins R; Armitage J; Parish S; Sleight P; Peto R;
Lancet; 2004 Mar; 363(9411):757-67. PubMed ID: 15016485
[TBL] [Abstract][Full Text] [Related]
39. The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients.
Degreef LE; Opdam FL; Teepe-Twiss IM; Jukema JW; Guchelaar HJ; Tamsma JT
Eur J Intern Med; 2010 Aug; 21(4):293-6. PubMed ID: 20603038
[TBL] [Abstract][Full Text] [Related]
40. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
